The decline of BCR-ABL/GUS ratio in CML patients treated upfront with nilotinib shows a rapid descent during the first trimester, and the responses are similar to those achieved with ABL as control
Servizos
Servizos
Data de publicación
2014Título da revista
Haematologica
Tipo de contido
Publicación de congreso
